Agile Therapeutics Inc

Agile Therapeutics Inc

AGRX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$10.43M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Agile Therapeutics IncAgile Therapeutics Inc-0.2-72%0.5-
$1.28

Current Fair Value

15.5% downside

Overvalued by 15.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$10.43 Million
Enterprise Value$7.87 Million
Earnings per Share$-6.71
Beta1.58
Outstanding Shares6,856,229

Return

Return on Equity72.37%ROE
Return on Assets-105.97%
Return on Invested Capital120.84%

Valuation & Multiples

P/E Ratio-0.23P/E Ratio
PEG-0.11PEG
Price to Sales0.5Price to Sales
Price to Book Ratio-0.38Price to Book Ratio
Enterprise Value to Revenue0.36
Enterprise Value to EBIT-0.58
Enterprise Value to Net Income-1
Total Debt to Enterprise0.04
Debt to Equity-0.01Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Agile Therapeutics Inc

CEO: Alfred Altomari

Agile Therapeutics Insider Information FAQ

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.